Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...

Reports Q4 revenue $39.22M, consensus $40.68M. “2024 was a challenging yet transformative year for PacBio (PACB), marked by the successful ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

“WVE-007 is also Wave’s first siRNA to enter clinical development and utilizes our state-of-the art chemistry delivering potentially ... “Risk Factors” in Wave’s most recent Annual Report on Form 10-K ...

Researchers at Jilin University (Changchun, China) developed a highly sensitive, rapid, and accurate method for analyzing ...

QuidelOrtho (NASDAQ:QDEL – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” ...

State of New Jersey Common Pension Fund D increased its stake in shares of QuidelOrtho Co. (NASDAQ:QDEL – Free Report) by 22.4% in the 4th quarter, according to the company in its most recent filing ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

Ottawa, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The global Immunoassay market is estimated to reach a valuation of USD 34,490 ...